Skip to content

Clinical study of ozone water for the treatment of bladder pain syndrome/interstitial cystitis

Clinical study of ozone water for the treatment of bladder pain syndrome/interstitial cystitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083297
Enrollment
Unknown
Registered
2024-04-19
Start date
2024-04-26
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder pain syndrome/interstitial cystitis

Interventions

Control group:Essential Medicines
treatment group:Essential Medicines + Ozone Water Therapy

Sponsors

Second Hospital of Tianjin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: ?Refer to the IC diagnostic criteria developed by the Guidelines for the Diagnosis and Treatment of Andrology Diseases in Urology in China;? Age 18~85 years old (inclusive), male or female;? In the awake state, the bladder capacity is > 150 mL (there is no urgency to urinate when the bladder is filled with 150ml of liquid);? The previous drug treatment or physical therapy effect was not good, and the drug has been stopped for 2 weeks;? The 24-hour average pain score was greater than 4 points and less than 8 points.? Able to comply with study and follow-up procedures;? Voluntarily participate in this clinical trial and sign the informed consent form of the subject;

Exclusion criteria

Exclusion criteria: ? Other patients with chemical cystitis or tuberculous cystitis; ? People with urinary tract infection; ? Bladder tumors; ? In the awake state, the bladder capacity < 150 mL;? Pregnant women;? Allergic constitution,G6PD deficiency(favism)and hyperthyroidism are contraindications to ozone therapy; ? Patients treated with intravenous copper or iron are contraindicated to ozone therapy; ? Those with major diseases of the heart, liver and other systems are excluded;? Exclusion of those with poor compliance;? Those who have participated in other clinical trials within 1 month before the start of this trial;

Design outcomes

Primary

MeasureTime frame
visual analogue scale(VAS);

Secondary

MeasureTime frame
Interstitial Cystitis Symptom Index Score (ICSI);Interstitial Cystitis Problem Index Score (ICPI);Quality of Life ( QOL);physically unclonable function (PUF);voiding diary(VD);

Countries

China

Contacts

Public ContactHuixing Wang , Yang Tang

Second Hospital of Tianjin Medical University

doctorhuixing@126.com+86 137 5244 0265

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026